UBS said it believes that upcoming data for Eli Lilly's (LLY) GLP-1 drug tirzepatide in the treatment of sleep apnea will come in below expectations.
https://seekingalpha.com/news/4079564-ubs-sees-lilly-glp-1sleep-apnea-study-falling-short-of-street-estimates
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.